Drug intelligence / Profile preview

TAK-058

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-058 (also known as ENV-8058) is an orally administered small molecule drug developed as a serotonin 3 (5-HT3) receptor antagonist. Its primary mechanism of action is antagonism of the serotonin 3 receptor. TAK-058 was originally developed by Envoy Therapeutics and later by Takeda following acquisition. The drug was investigated for the treatment of cognitive impairment associated with schizophrenia and other neuropsychiatric disorders such as anxiety, depression, eating disorders, Parkinson's disease, and Huntington's disease. Clinical development reached phase 1 trials in schizophrenia but has since been discontinued[1][2][3][4].

Other names: tak-058tak058tak 058env-8058env8058env 8058

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on TAK-058.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-058.

Explore the full profile